Is cyproterone only for women, or can men use it too?

Cyproterone acetate, commonly abbreviated as CPA in medical literature, is a synthetic steroidal compound with powerful antiandrogenic and progestogenic effects.

Although it has been traditionally prescribed more often to women, particularly for conditions like acne, hirsutism, and polycystic ovary syndrome (PCOS), it is not licensed for women only. Prescribing information and published clinical reports describe use in male patients as well, but only under specific clinical scenarios and not without controversy.

Understanding what it means for a drug to be "antiandrogenic" is crucial. Antiandrogens are substances that block the biological effects of androgens, which are male sex hormones like testosterone and dihydrotestosterone (DHT). Cyproterone achieves this in two ways. First, it competes with androgens for receptor binding sites in various tissues. Second, it suppresses the release of gonadotropins from the hypothalamus, which in turn lowers the production of testosterone in the testes. The outcome is a notable reduction in circulating testosterone and a decreased androgenic effect at the cellular level.

While public narratives and even some treatment guidelines tend to associate CPA use with women's health issues, the drug has also been clinically employed in men—particularly in the treatment of prostate cancer, certain paraphilic disorders, and within gender-affirming hormone therapy for transgender women. However, its use in male populations remains selective and is shaped by ongoing debates about its safety profile and long-term outcomes. In prostate cancer—a hormonally dependent malignancy—cyproterone has been used to slow tumour progression by suppressing testosterone. A randomised trial published in European Urology compared CPA with another antiandrogen, flutamide. The EORTC 30892 trial randomised 310 men with metastatic prostate cancer to flutamide or cyproterone acetate monotherapy, and the final analysis was published in 2004.

The investigators reported no statistically significant difference in overall survival between the two drugs, and noted that the trial was too small to rule out a moderate difference. That is a much weaker basis for choosing between antiandrogens than a large trial would give, and it is one reason CPA is not a first-line option in this setting. In another context, cyproterone has been used in Europe to manage paraphilic disorders—conditions characterised by intense sexual urges toward socially or legally unacceptable targets. The published evidence here comes largely from small, uncontrolled case series and clinical practice guidelines rather than from randomised trials, and there is no large controlled human trial that settles how well it works or how safely. The absence of control groups and the reliance on self-reported outcomes limit what can be concluded, and caution against generalising from those reports.

The risk profile of cyproterone has drawn increasing attention, especially following a 2020 safety review by the European Medicines Agency (EMA). The EMA reported that meningiomas—a type of usually benign brain tumour—have been seen mainly in people taking 25 mg a day or more for several years, and that the risk rises as the cumulative dose rises. Based on these findings, the EMA restricted the use of higher-dose CPA, recommending that medicines containing 10 mg or more be used for hirsutism, androgenic alopecia, acne and seborrhoea only after other options have failed, and that treatment be stopped permanently if a meningioma is diagnosed. While the EMA did not describe causality as definitively established, the strength of the association led to regulatory action.

Despite its documented use in male populations, cyproterone acetate has not received approval from the U.S. Food and Drug Administration (FDA) for any indication. The FDA has not published a detailed rationale, so any explanation for that is inference rather than a stated position.

Cyproterone is not a gender-exclusive drug. However, nothing here should be read as a statement that it is safe for a given person, and its use is not something to generalise from other people's regimens.

Its pharmacological action on sex hormones makes it a powerful therapeutic agent but also a compound that demands close monitoring. Published reports describe effects in very specific male health conditions, and also serious potential risks, especially with prolonged or high-dose use. National regulations vary, reflecting divergent interpretations of the scientific evidence.

Cyproterone is also a known teratogen. Product information contraindicates it in pregnancy, and people who could become pregnant are advised to use effective contraception during treatment and to avoid handling broken or crushed tablets.

Talk to a doctor or pharmacist before starting, stopping or combining cyproterone acetate, and do not adjust a prescribed dose on your own.

User Experiences: Can Men Use Cyproterone?

Some users have experimented with cyproterone alongside other treatments. One user described an aggressive anti-androgen regimen combining oral CPA, topical minoxidil, dutasteride, and bicalutamide. Despite this, they still reported follicle miniaturisation. Stacking several systemic anti-androgens like this has not been studied for safety, and each of those drugs carries its own risks; a prescriber should be involved before anything of the kind is considered. Other posters raised topical research compounds such as RU58841 or pyrilutamide as alternatives they believed acted less systemically—these are experimental compounds that are not approved as medicines anywhere, have no published long-term human safety data, and cannot be described as safe.

Another member considered using CPA as a short-term strategy to reverse hair loss, followed by finasteride for maintenance. However, concerns about CPA's testosterone-lowering effects and associated health risks—such as liver strain and the reported meningioma risk with long-term, higher-dose use—prompted discussions around alternatives like spironolactone (Reddit).

In contrast, transgender women and nonbinary individuals undergoing hormone therapy have shared largely positive outcomes with CPA, often used in combination with estradiol and minoxidil. These users report meaningful regrowth and reduced shedding as part of broader hormone replacement regimens. However, it's important to note that these individuals typically seek systemic suppression of testosterone for gender-affirming purposes, not merely for hair preservation.

In summary, CPA suppresses androgens, but its systemic effects—especially testosterone suppression—are the reason most community discussion steers cisgender men with androgenic alopecia elsewhere. Community users commonly say they prefer finasteride or dutasteride, which are licensed medicines with published trial data, and a doctor is the right person to weigh any of these options for an individual.

References

Schröder, F. H., Whelan, P., de Reijke, T. M., Kurth, K. H., Pavone-Macaluso, M., Mattelaer, J., van Velthoven, R. F., Debois, M., & Collette, L. (2004). Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. European Urology, 45(4), 457–464. https://pubmed.ncbi.nlm.nih.gov/15041109/

European Medicines Agency. (2020). EMA restricts use of cyproterone-containing medicines due to meningioma risk. https://www.ema.europa.eu/en/news/ema-restricts-use-cyproterone-containing-medicines-due-meningioma-risk

Reddit. (2022, December 6). Extreme regimen and still miniaturized hairs. AGA is just impossible to beat. Retrieved from https://reddit.com/r/tressless/comments/zeg4vo/extreme_regimen_and_still_miniaturized_hairs_aga/

Reddit. (2025, June 21). Cypro to reverse hairloss + Fin? Retrieved from https://reddit.com/r/tressless/comments/1lgs1tm/cypro_to_reverse_hairloss_fin/

Reddit. (2024, August 27). 5 months of nuking T, 2 months of minoxidil. Retrieved from https://reddit.com/r/tressless/comments/1f2uc8c/5_months_of_nuking_t_2_months_of_minoxidil/

Reddit. (2023, September 16). Hair follicles do die - my “hair” is the proof of that statement. Retrieved from https://reddit.com/r/tressless/comments/16kga1t/hair_follicles_do_die_my_hair_is_the_proof_of/